Press Releases

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Trading update

Strong H2 momentum expected to deliver double-digit annual growth but below expectations

Deferred revenue opportunities, investment in offering and further new initiatives expected to drive resumption of stronger subsequent growth

Manchester, UK – 8 February 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, provides an update on current trading for the second half of the financial year to 31 March 2021 (“H2”).

Whilst

Yourgene Health plc
("Yourgene" or the "Group" or the "Company")

DPYD screening recommended in Belgium

Manchester, UK – 13 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the research article published on 11 January 2021, in Acta Clinica Belgica, titled: ‘Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).’

The research article endorses screening for Dihydropyrimidine Dehydrogenase (DPD) deficiency which can cause severe and sometimes lethal side

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Clarigene® SARS-CoV-2 Product Update
and Partnerships with CityDoc and ReCoVa-19

Manchester, UK – 11 January 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following the Company’s statement on 24 December 2020, regarding the new virus strain (VUI-202012/01 SARS-CoV-2 variant), Yourgene’s wet lab testing is now complete and has confirmed that the performance of the Clarigene ^® SARS-CoV-2 assay is not impacted by any currently

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

COVID-19 update: approved provider for UK Government and r esponse to new virus strain

Manchester, UK – 24 December 2020:  Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that Yourgene Genomic Services has been added to the UK Government’s approved COVID-19 private testing providers list for the Test to Release for International Travel scheme introduced on 15 December 2020 (“Test to Release”), and also for

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Half-year Report

Manchester, UK – 17 December 2020: Yourgene Health plc (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces its unaudited half-year report for the six months ended 30 September 2020.

The results demonstrate the resilience of the Group’s core business during the first few months of the global pandemic, its responsiveness in launching COVID-19 testing solutions rapidly and its

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

DPYD kits recommended by NHS England

Manchester, UK – 2 December 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, welcomes the Clinical Commissioning Urgent Policy Statement, published by NHS England, titled: ‘Pharmacogenomic testing for DPYD polymorphisms with fluoropyrimidine therapies’ recommending the routine availability of DPYD testing prior to the start of treatment with chemotherapeutic drug 5-Fluorouracil (5-FU), to identify the risk of severe side effects.

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Directorate change
Chief Scientific Officer appointment to drive new product development roadmap

Manchester, UK – 5 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces the appointment of Dr. Joanne Mason as Chief Scientific Officer as a director of the Company with immediate effect.

Dr Mason has been director of Research & Development (non-board position) at Yourgene since joining the Company in December 2019,

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Partnership with Take2 Health Limited
Yourgene to run genomic test for Nasopharyngeal Carcinoma (NPC) Screening in Taiwan

Manchester, UK – 3 November 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that its wholly-owned subsidiary, Yourgene Health Taipei, has signed a regional marketing and services agreement (the “Agreement”) with Hong Kong based Take2 Health Limited (“Take2”), to promote Take2’s clinically-validated genomic test for Nasopharyngeal Carcinoma

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Half-year Trading update
H1 year-on-year growth demonstrating the resilience of the Company

Manchester, UK – 26 October 2020: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces a trading update for the half-year ended 30 September 2020 (“H1 2020”).

Revenues for the half-year ended 30 September 2020 were £8.2m (H1 2019: £7.8m), up 5% compared to the previous year, with strong European revenues offsetting the

Yourgene Health plc
(“Yourgene Health” or the "Company")

CQC registration

Manchester, UK – 23 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces that it has received notification from the Care Quality Commission (“CQC”) that the Company’s facilities at Citylabs 1.0 in Manchester are now a second registered location from which to perform diagnostics and screening procedures.

The extension of the Company’s current CQC registration allows NIPT testing greater flexibility to operate

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Yourgene Genomic Services collaboration with Cytox

Partnership with Cytox to enable clinical access to genoSCORE™ - a new genetic test to determine the risk of developing Alzheimer’s disease

Manchester, UK – 21 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces a new collaboration between the recently launched Yourgene Genomic Services (“YGS”) and Cytox Ltd (“Cytox”), for a beta-testing genomic study on their

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Elucigene DPYD tests to be used routinely in Wales

Wales is first UK nation to offer DPYD screening to patients undergoing chemotherapy
DPYD tests screen patients to identify risk of severe side effects from certain chemotherapy treatments

Manchester, UK – 12 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces its oncology product, Elucigene DPYD test, is now being used in Wales to routinely

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

Strategic reproductive health partnership secured in Japan

Manchester, UK – 8 October 2020: Yourgene Health (AIM: YGEN), a leading international molecular diagnostics group, announces it has entered into a 5-year strategic partnership with a blue chip Japanese multinational to provide Yourgene’s Flex™ Analysis Software (“ Flex Software”) bioinformatics platform for a reproductive health project.

Yourgene and the Japanese partner (the “Partner”) have entered into a technology transfer

Yourgene Health plc

(“Yourgene” or the “Group” or the “Company”)

IONA ^® Nx awarded contract with St George’s NHS Hospital

Manchester, UK – 7 October 2020: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that it has been awarded the contract for non-invasive prenatal testing (NIPT) using its newly-launched IONA ^® Nx NIPT Workflow ('IONA ^® Nx'), by the prestigious St George’s NHS Trust Foundation in Tooting, South London (“St George’s”). The contract, subject to signing by both